The Effects of Real-World Evidence on the Treatment of HER2+ mBC : Episode 13

News

Video

November 16, 2023

Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC

Author(s):

Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.

EP: 1.Evolution of Advanced HER2+ Breast Cancer Management

EP: 2.Current Standard of Care for HER2+ Metastatic Breast Cancer (mBC)

EP: 3.The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC

EP: 4.Approaches to Sequencing Therapies for HER2+ mBC

EP: 5.Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC

EP: 6.Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC

EP: 7.Global Perspectives: Evolution of Advanced HER2+ Breast Cancer Treatment

EP: 8.Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)

EP: 9.Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan

EP: 10.Novel Therapies Under Investigation for HER2+ mBC

EP: 11.Treatment Sequencing Approaches for Patients With HER2+ mBC

EP: 12.French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC

Now Viewing

EP: 13.Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC

EP: 14.Treatment Approaches for Patients With HER2+ mBC and Brain Metastases

EP: 15.Novel Treatment Approaches Under Investigation for HER2+ mBC

Related Content

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

January 13th 2025

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI

December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

December 26th 2024

Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer